Neuropace, Inc. NPCE Investments Fair Value Disclosure
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentsFairValueDisclosure.
The official record: Neuropace, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neuropace, Inc.'s investments fair value disclosure.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neuropace, Inc.'s investments fair value disclosure?
- Neuropace, Inc. (NPCE) reported investments fair value disclosure of $39.2M in Q1 2026.
- How has Neuropace, Inc.'s investments fair value disclosure changed year-over-year?
- Neuropace, Inc.'s investments fair value disclosure decreased by 0.1% year-over-year, from $39.24M to $39.2M.
- What is the long-term trend for Neuropace, Inc.'s investments fair value disclosure?
- Over 5 years (2020 to 2025), Neuropace, Inc.'s investments fair value disclosure has grown at a 27.5% compound annual growth rate (CAGR), from $11.69M to $39.37M.